A Study of the Dose Proportionality of Extended Release Paliperidone

NCT00791167 | Completed Phase 1

• 1 other identifier: CR011437
• Study Type: interventional
• Target: 58
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purposes of this study are to evaluate the dose proportionality of 1.5- and 3 mg tablets of paliperidone ER, to document the pharmacokinetics of a 1.5 mg dose of paliperidone ER, and to assess the safety and tolerability of the 1.5- and 3 mg tablets in healthy men.

Conditions

Schizophrenia

Keywords

Mood Disorders, Antipsychotic drugs; Schizophrenia; Paliperidone ER

Outcome Measures

Primary Outcomes (1)

• To evaluate dose-proportionality of 1.5 and 3-mg tablets of paliperidone ER

Secondary Outcomes (1)

• To document the pharmacokinetics of a 1.5-mg dose of paliperidone ER in healthy men and to assess the safety and tolerability of the 1.5- and 3 mg tablets of paliperidone ER in healthy men

Interventions

Paliperidone ER DRUG

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Body mass index ( weight \[kg\]/height \[m2\]) of 18 to 30 kg/m2, inclusive
• Have a supine (after 5 minutes rest) blood pressure between 100 and 140 mmHg systolic, inclusive, and 50 and 90 mmHg diastolic, inclusive
• Healthy on the basis of a prestudy physical examination, medical history, 12-lead ECG, and the laboratory results of serum chemistry, hematology, and urinalysis performed within 21 days before the first dose. If the results of the serum chemistry, hematology, or urinalysis testing are not within the laboratory's reference ranges, the volunteer can be included only if the investigator judges that the deviations are not clinically significant. For renal function tests, the values must be within the normal laboratory reference ranges

You may not qualify if:

• Known drug allergy to risperidone, paliperidone, or any of its excipients
• Known history of drug-induced dystonia
• Recent history of alcohol or substance abuse
• Relevant history or presence of any cardiovascular (including myocardial infarct or cardiac arrhythmia), respiratory, neurologic (including seizures), psychiatric, renal, hepatic, gastrointestinal (including surgeries, severe gastrointestinal narrowing, and malabsorption problems), endocrine, hematologic, or immunologic disease
• History of any cancer, with the exception of basal cell carcinoma
• At screening, has signs of autonomic dysfunction as indicated by a sustained decrease of \> 20 mmHg in systolic blood pressure or a decrease of \>10 mmHg in diastolic blood pressure after standing for at least 2 minutes that is not associated with an increase of \>15 beats per minute (bpm) in heart rate
• Bradycardia (heart rate \<50 bpm) as determined by screening 12-lead ECG
• A positive test result (or history of) for any of the serology tests (hepatitis B and C, and human immunodeficiency virus) at screening
• History of smoking or use of nicotine-containing substances within the last 2 months, as determined by medical history and/or volunteer's verbal report. Volunteers must agree to refrain from use throughout the study
• Use of any prescription or nonprescription medication (including vitamins and herbal supplements) within 14 days before the first dose of study drug. Exception for acetaminophen (paracetamol) or ibuprofen, which is allowed up to 3 days before first dose of study drug

Sponsors & Collaborators

• Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: lead

Related Links

• A study of the dose proportionality of extended release paliperidone

MeSH Terms

Conditions

Schizophrenia; Mood Disorders

Interventions

Paliperidone Palmitate

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines

Study Officials

• Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial

  Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 13, 2008
• First Posted: November 14, 2008
• Study Start: June 1, 2006
• Study Completion: August 1, 2006
• Last Updated: May 18, 2011

Record last verified: 2009-02